miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents

2013 ◽  
Vol 13 (5) ◽  
pp. 519-541 ◽  
Author(s):  
Biyun Qian ◽  
Subhasree Nag ◽  
Yuliang Su ◽  
Sukesh Voruganti ◽  
Jiang-Jiang Qin ◽  
...  
2013 ◽  
Vol 85 (11) ◽  
pp. 1579-1587 ◽  
Author(s):  
Muthu K. Shanmugam ◽  
Xiaoyun Dai ◽  
Alan Prem Kumar ◽  
Benny K.H. Tan ◽  
Gautam Sethi ◽  
...  

2019 ◽  
Vol 12 (2) ◽  
pp. 68 ◽  
Author(s):  
S. Franklyn De Silva ◽  
Jane Alcorn

Cancer causes considerable morbidity and mortality across the world. Socioeconomic, environmental, and lifestyle factors contribute to the increasing cancer prevalence, bespeaking a need for effective prevention and treatment strategies. Phytochemicals like plant polyphenols are generally considered to have anticancer, anti-inflammatory, antiviral, antimicrobial, and immunomodulatory effects, which explain their promotion for human health. The past several decades have contributed to a growing evidence base in the literature that demonstrate ability of polyphenols to modulate multiple targets of carcinogenesis linking models of cancer characteristics (i.e., hallmarks and nutraceutical-based targeting of cancer) via direct or indirect interaction or modulation of cellular and molecular targets. This evidence is particularly relevant for the lignans, an ubiquitous, important class of dietary polyphenols present in high levels in food sources such as flaxseed. Literature evidence on lignans suggests potential benefit in cancer prevention and treatment. This review summarizes the relevant chemical and pharmacokinetic properties of dietary polyphenols and specifically focuses on the biological targets of flaxseed lignans. The consolidation of the considerable body of data on the diverse targets of the lignans will aid continued research into their potential for use in combination with other cancer chemotherapies, utilizing flaxseed lignan-enriched natural products.


2013 ◽  
Vol 13 (5) ◽  
pp. 506-518 ◽  
Author(s):  
Yujiong Wang ◽  
Yong Li ◽  
Xiaoming Liu ◽  
William Cho

2016 ◽  
Vol 2016 ◽  
pp. 1-17 ◽  
Author(s):  
Rosa Lauretta ◽  
Giulia Lanzolla ◽  
Patrizia Vici ◽  
Luciano Mariani ◽  
Costanzo Moretti ◽  
...  

Preclinical, early phase clinical trials and epidemiological evidence support the potential role of insulin-sensitizers in cancer prevention and treatment. Insulin-sensitizers improve the metabolic and hormonal profile in PCOS patients and may also act as anticancer agents, especially in cancers associated with hyperinsulinemia and oestrogen dependent cancers. Several lines of evidence support the protection against cancer exerted by dietary inositol, in particular inositol hexaphosphate. Metformin, thiazolidinediones, and myoinositol postreceptor signaling may exhibit direct inhibitory effects on cancer cell growth. AMPK, the main molecular target of metformin, is emerging as a target for cancer prevention and treatment. PCOS may be correlated to an increased risk for developing ovarian and endometrial cancer (up to threefold). Several studies have demonstrated an increase in mortality rate from ovarian cancer among overweight/obese PCOS women compared with normal weight women. Long-term use of metformin has been associated with lower rates of ovarian cancer. Considering the evidence supporting a higher risk of gynaecological cancer in PCOS women, we discuss the potential use of insulin-sensitizers as a potential tool for chemoprevention, hypothesizing a possible rationale through which insulin-sensitizers may inhibit tumourigenesis.


Sign in / Sign up

Export Citation Format

Share Document